Hongjin Wang

机构：Dalian Medical University, Second Affiliated Hospital of Dalian Medical University · ORCID：0009-0008-8649-7535

发表论文 39 篇 · 总被引 455 次 · h-index 7

代表论文

• A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer (2023 · Advanced Science · 被引 46)
• Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy (2025 · Advanced Materials · 被引 28)
• Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy (2025 · Nature Communications · 被引 13)
• A Multifunctional Fe-EGCG@RSL3 Nanomedicine Synergizes Ferroptosis Induction and Tumor Microenvironment Remodeling for Enhanced Bladder Cancer Immunotherapy (2025 · Research · 被引 12)
• Clinical study reveals the efficacy of sirolimus in treating primary immune thrombocytopenia: findings from a single-center study (2024 · Blood Coagulation & Fibrinolysis · 被引 7)
• Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy (Adv. Mater. 39/2025) (2025 · Advanced Materials · 被引 5)